1. Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture
- Author
-
Ministerio de Ciencia e Innovación (España), Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, Fundació La Marató de TV3, García-Crespo, Carlos, de Ávila, Ana Isabel, Gallego, Isabel, Soria, María Eugenia, Durán-Pastor, Antoni, Somovilla, Pilar, Martínez-González, Brenda, Muñoz-Flores, Javier, Mínguez, Pablo, Salar-Vidal, Llanos, Esteban-Muñoz, Mario, Cañar-Camacho, Elizabeth, Ferrer-Orta, Cristina, Zuñiga, Sonia, Solá Gurpegui, Isabel, Enjuanes, Luis, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Gómez, Jordi, Verdaguer, Núria, Domingo, Esteban, Perales, Celia, Ministerio de Ciencia e Innovación (España), Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, Fundació La Marató de TV3, García-Crespo, Carlos, de Ávila, Ana Isabel, Gallego, Isabel, Soria, María Eugenia, Durán-Pastor, Antoni, Somovilla, Pilar, Martínez-González, Brenda, Muñoz-Flores, Javier, Mínguez, Pablo, Salar-Vidal, Llanos, Esteban-Muñoz, Mario, Cañar-Camacho, Elizabeth, Ferrer-Orta, Cristina, Zuñiga, Sonia, Solá Gurpegui, Isabel, Enjuanes, Luis, Esteban, Jaime, Fernández-Roblas, Ricardo, Gadea, Ignacio, Gómez, Jordi, Verdaguer, Núria, Domingo, Esteban, and Perales, Celia
- Abstract
There is a need for effective anti-COVID-19 treatments, mainly for individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug repositioning has proved effective in identifying drugs that can find a new application for the control of coronavirus disease, in particular COVID-19. The purpose of the present study was to find synergistic antiviral combinations for COVID-19 based on lethal mutagenesis.
- Published
- 2024